TY  - GEN
AB  - T cell function is regulated by cytokines and receptor expression, notably IL-2 and CD25. While murine CD25 expression is largely restricted to Tregs, humans exhibit a CD25^low/intermediate FOXP3^– memory subset previously thought to be recently activated. We show this population is quiescent, phenotypically distinct from CD25^– memory cells, and differentially affected by IL-2 therapy in cancer patients, with no murine equivalent—highlighting translational limitations. Additionally, we demonstrate that combining OX40 agonist therapy with TGF-β receptor inhibition eradicates large tumors in mice, enhancing CD8+ T cell proliferation and function. These findings inform IL-2/CD25-targeted therapies and novel cancer immunotherapy strategies.
AD  - Oregon Health and Science University
AU  - Triplett, Todd
DA  - 2012
DO  - 10.6083/M4K0729M
DO  - DOI
ED  - Weinberg, Andrew
ED  - Advisor
ID  - 782
KW  - Immunotherapy
KW  - Interleukin-2
KW  - T-Lymphocytes
KW  - CD4-Positive T-Lymphocytes
KW  - Transforming Growth Factor beta
KW  - Mice
KW  - Neoplasms
L1  - https://digitalcollections.ohsu.edu/record/782/files/785_etd.pdf
L2  - https://digitalcollections.ohsu.edu/record/782/files/785_etd.pdf
L4  - https://digitalcollections.ohsu.edu/record/782/files/785_etd.pdf
LK  - https://digitalcollections.ohsu.edu/record/782/files/785_etd.pdf
N2  - T cell function is regulated by cytokines and receptor expression, notably IL-2 and CD25. While murine CD25 expression is largely restricted to Tregs, humans exhibit a CD25^low/intermediate FOXP3^– memory subset previously thought to be recently activated. We show this population is quiescent, phenotypically distinct from CD25^– memory cells, and differentially affected by IL-2 therapy in cancer patients, with no murine equivalent—highlighting translational limitations. Additionally, we demonstrate that combining OX40 agonist therapy with TGF-β receptor inhibition eradicates large tumors in mice, enhancing CD8+ T cell proliferation and function. These findings inform IL-2/CD25-targeted therapies and novel cancer immunotherapy strategies.
PB  - Oregon Health and Science University
PY  - 2012
T1  - Identification of a novel human CD4+ T cell population and overcoming the immunosuppressive environment in large established tumors
TI  - Identification of a novel human CD4+ T cell population and overcoming the immunosuppressive environment in large established tumors
UR  - https://digitalcollections.ohsu.edu/record/782/files/785_etd.pdf
Y1  - 2012
ER  -